




# PHARMACEUTICAL 2022

Arcutis Biotherapeutics Inc.  
Rank 238 of 466





## PHARMACEUTICAL 2022

Arcutis Biotherapeutics Inc.  
Rank 238 of 466

The relative strengths and weaknesses of Arcutis Biotherapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Arcutis Biotherapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 69% points. The greatest weakness of Arcutis Biotherapeutics Inc. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 51% points.

The company's Economic Capital Ratio, given in the ranking table, is 118%, being 40% points above the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	402,773
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	33,326
Liabilities, Non-Current	77,149
Other Assets	3,118
Other Compr. Net Income	-253
Other Expenses	0
Other Liabilities	0
Other Net Income	173
Other Revenues	0
Property and Equipment	2,261
Research and Development	145,558
Selling, General and Administrative Expense	60,971

Output Variable	Value in 1000 USD
Assets	408,152
Liabilities	110,475
Expenses	206,529
Revenues	0
Stockholders Equity	297,677
Net Income	-206,356
Comprehensive Net Income	-206,482
Economic Capital Ratio	118%